FDA Implements Real-Time Reviews of Clinical Trial Data

The U.S. Food and Drug Administration announced the start of an initiative to implement real-time clinical trials (RTCT) in an April 28, 2026 press release. Per the FDA release, the agency has initiated 2 proof-of-concept trials that will report endpoints and data signals to the agency in real time and has issued a Request for Information (RFI) on a proposed pilot program slated to start this summer. The FDA named AstraZeneca and Amgen as the sponsors of the first trials: AstraZeneca's Phase 2 multi-site TRAVERSE study in treatment‑naive mantle cell lymphoma and Amgen's Phase 1b STREAM‑SCLC study in limited‑stage small cell lung carcinoma, with participating sites for AstraZeneca including MD Anderson Cancer Center and University of Pennsylvania, per the FDA release and MedPageToday. The agency reports it has received and validated signals from the AstraZeneca trial through Paradigm Health, according to the FDA and Reuters.

Per the FDA announcement, the proofs-of-concept are configured to transmit pre‑agreed safety signals and clinical endpoints to agency reviewers in near real time rather than following the traditional sponsor‑to‑agency submission cadence. Reuters reports that the agency would receive aggregated signal data-examples cited include rates of adverse events or tumor response percentages-rather than underlying individual patient records. The FDA press release frames the initiative as a step to enable FDA scientists to view safety and efficacy indicators as a trial progresses. WSJ and STAT reporting add that the move aims to reduce manual data extraction and sponsor-side preprocessing that currently slow regulatory review.

Industry observers note that real-time regulatory review raises immediate demands on data interoperability, validation, and provenance. Systems that feed aggregated signals into regulators must implement consistent mappings from electronic health record (EHR) source fields to standardized clinical endpoints and demonstrate traceability from an aggregated flag back to the originating site-level evidence. Observers also highlight that aggregated-signal pipelines change the unit of verification for regulators: instead of reprocessing raw case report forms, reviewers will need robust metadata and audit trails that justify an aggregate metric.

Editorial analysis: For the broader ecosystem, the FDA's pilot represents a material shift in how regulators interact with trial data and how sponsors and vendors design trial IT stacks. Real-time review could compress detection-to-action cycles for safety signals and accelerate decision points in development programs. At the same time, the approach surfaces technical and governance questions-data standardization, vendor certification, privacy-preserving aggregation methods, and how sponsors document analytic transforms-that will determine whether real-time reviews are operationally feasible and legally robust.

For practitioners: follow three indicators in the coming months. First, the RFI responses and pilot design documents for standards referenced (for example, FHIR, CDISC, or bespoke schemas). Second, technical details published about the Paradigm Health integration and the validation steps the FDA used to accept aggregated signals. Third, privacy and audit-capability specifications showing how provenance and reproducibility will be preserved when regulators consume aggregated metrics rather than raw records. Outcomes from the AstraZeneca and Amgen proofs-of-concept will likely shape the scope and technical requirements of any broader rollout.